KRW 5620.0
(2.37%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -1090.00 KRW | -164.66% |
2022 | 1685.89 KRW | -28.32% |
2021 | 2352.10 KRW | 180.15% |
2020 | -2934.51 KRW | -279.19% |
2019 | -773.88 KRW | 86.67% |
2018 | -5806.60 KRW | -153.33% |
2017 | -2292.09 KRW | -1088.47% |
2016 | -192.86 KRW | -3.07% |
2015 | -187.12 KRW | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | 115.86 KRW | 144.85% |
2024 Q1 | -258.34 KRW | 28.62% |
2023 Q3 | -401.56 KRW | -979.75% |
2023 Q1 | -291.15 KRW | 80.94% |
2023 FY | - KRW | -164.66% |
2023 Q4 | -361.91 KRW | 9.87% |
2023 Q2 | -37.19 KRW | 87.23% |
2022 Q1 | 2253.93 KRW | 210.64% |
2022 FY | - KRW | -28.32% |
2022 Q4 | -1527.74 KRW | -960.36% |
2022 Q3 | 177.57 KRW | -79.97% |
2022 Q2 | 886.69 KRW | -60.66% |
2021 Q1 | 369.73 KRW | 72.31% |
2021 Q2 | -36.64 KRW | -109.91% |
2021 Q3 | 1299.57 KRW | 3646.86% |
2021 FY | - KRW | 180.15% |
2021 Q4 | 725.58 KRW | -44.17% |
2020 Q4 | 214.57 KRW | 110.69% |
2020 Q2 | -1067.32 KRW | -583.22% |
2020 Q1 | -156.22 KRW | 58.7% |
2020 FY | - KRW | -279.19% |
2020 Q3 | -2006.44 KRW | -87.99% |
2019 Q3 | -131.08 KRW | 8.8% |
2019 FY | - KRW | 86.67% |
2019 Q4 | -378.30 KRW | -188.6% |
2019 Q2 | -143.73 KRW | -33.18% |
2019 Q1 | -107.92 KRW | -116.66% |
2018 Q3 | -5895.04 KRW | 0.0% |
2018 Q4 | -49.81 KRW | 99.16% |
2018 FY | - KRW | -153.33% |
2017 FY | - KRW | -1088.47% |
2016 FY | - KRW | -3.07% |
2015 FY | - KRW | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 9148.00 KRW | 111.915% |
InBody Co.,Ltd | 2819.01 KRW | 138.666% |
Curexo Inc. | -120.00 KRW | -808.333% |
Seegene, Inc. | 14.19 KRW | 7781.466% |
i-SENS, Inc. | 134.89 KRW | 908.066% |
Ray Co., Ltd. | -140.25 KRW | -677.184% |
Gencurix Inc. | -1629.25 KRW | 33.098% |
L&C Bio Co., Ltd | 2096.33 KRW | 151.996% |